Perbedaan Brigit Biofarmaka Teknologi Tbk. dan Saraswanti Indoland Development Tbk.: Brigit Biofarmaka Teknologi Tbk. diperdagangkan di Rp254 (kapitalisasi pasar 172,82 M, volume 24 jam 592,2 rb), sedangkan Saraswanti Indoland Development Tbk. diperdagangkan di Rp92 (kapitalisasi pasar 490,04 M, volume 24 jam 1,51 jt). Perbedaan utamanya: Saraswanti Indoland Development Tbk. jauh lebih besar — sekitar 2,8× kapitalisasi pasar Brigit Biofarmaka Teknologi Tbk., dan Saraswanti Indoland Development Tbk. lebih aktif diperdagangkan (1,51 jt vs 592,2 rb). Mana yang lebih baik tergantung tujuan investasimu.
| OBAT | SWID | |
|---|---|---|
Kapitalisasi Pasar | 172,82 M | 490,04 M |
Volume | 592,2 rb | 1,51 jt |
Lot | 5,92 rb | 15,14 rb |
Perputaran | 147,05 jt | 137,63 jt |
Harga Rata-rata | 248,31 | 90,94 |
Nilai Transaksi | 147,05 jt | 137,63 jt |
Harga Ekuilibrium Indikatif | 254 | 92 |
Volume Ekuilibrium Indikatif | 10 | 1,49 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Selengkapnya di halaman OBAT →PT Saraswanti Indoland Development Tbk ( The Company) was established on August 2, 2010 based on the Deed of Notary Ismaryani, SH, MKn. Number : 01. The deed of establishment of the Company was approved by the Minister of Law and Human Rights of the Republic of Indonesia number: AHU41610.AH.01.01.Tahun 2010. The Company started its commercial operations in 2011.
Selengkapnya di halaman SWID →